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Background: Expression of miR-17-92 enhances T-cell survival and interferon (IFN)-γ production. We previously
reported that miR-17-92 is down-regulated in T-cells derived from glioblastoma (GBM) patients. We hypothesized
that transgene-derived co-expression of miR17-92 and chimeric antigen receptor (CAR) in T-cells would improve
the efficacy of adoptive transfer therapy against GBM.
Methods: We constructed novel lentiviral vectors for miR-17-92 (FG12-EF1a-miR-17/92) and a CAR consisting of an
epidermal growth factor receptor variant III (EGFRvIII)-specific, single-chain variable fragment (scFv) coupled to the
T-cell receptor CD3ζ chain signaling module and co-stimulatory motifs of CD137 (4-1BB) and CD28 in tandem
(pELNS-3C10-CAR). Human T-cells were transduced with these lentiviral vectors, and their anti-tumor effects were
evaluated both in vitro and in vivo.
Results: CAR-transduced T-cells (CAR-T-cells) exhibited potent, antigen-specific, cytotoxic activity against U87 GBM
cells that stably express EGFRvIII (U87-EGFRvIII) and, when co-transduced with miR-17-92, exhibited improved
survival in the presence of temozolomide (TMZ) compared with CAR-T-cells without miR-17-92 co-transduction. In
mice bearing intracranial U87-EGFRvIII xenografts, CAR-T-cells with or without transgene-derived miR-17-92
expression demonstrated similar levels of therapeutic effect without demonstrating any uncontrolled growth of
CAR-T-cells. However, when these mice were re-challenged with U87-EGFRvIII cells in their brains, mice receiving
co-transduced CAR-T-cells exhibited improved protection compared with mice treated with CAR-T-cells without
miR-17-92 co-transduction.
Conclusion: These results warrant the development of novel CAR-T-cell strategies that incorporate miR-17-92 to
improve therapeutic potency, especially in patients with GBM.
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Although the central nervous system (CNS) is often con-
sidered to be immunologically privileged [1], recent vac-
cine studies in patients with malignant glioma reviewed in
[2,3], including ours [4], have demonstrated promising
results. However, vaccine efficacy, which relies on intact
host-immune activity, can suffer from systemic suppres-
sion of immunity due to tumor expression of immunosup-
pressive cytokines as well as chemo- and radiotherapy. On
the other hand, adoptive cell transfer (ACT) therapy with
autologous T-cells, especially using T-cells transduced
with chimeric antigen receptors (CARs), has shown prom-
ise in pilot hematologic cancer trials [5-8]. ACT with
CAR-T-cells may be particularly suitable for patients with
glioblastoma (GBM) because the specificity, number, and
functional phenotype of cells prepared ex vivo can be con-
trolled and manipulated far better than native T-cells in-
duced by in vivo immunization.
CARs offer several advantages compared with trad-
itional T-cell receptor (TCR)-mediated targeting of tumor
antigens. Unlike TCRs, CARs do not require antigen-
presentation by major histocompatibility complex (MHC),
which is often down-regulated in gliomas [9,10]. CARs
have evolved over the last decade, with progressively
increasing co-stimulatory activity. In addition to a single
signaling unit derived from the CD3ζ chain, second ge-
neration CARs incorporate the intracellular domain of a
co-stimulatory molecule, CD28 or tumor necrosis factor
(TNF) receptor family member, CD137 (4-1BB). Subse-
quent incorporation of both CD28 and CD137 has en-
hanced the ability of these receptors to stimulate cytokine
secretion and hence the antitumor efficacy of third gener-
ation CARs [11-14]. Recently, autologous CAR-modified
T-cells re-infused into 3 patients with refractory chronic
lymphocytic leukemia led to complete remission in 2 of
the 3 patients [5,6]; engineered cells persisted at high levels
for 6 months and continued to express the CAR [6]. These
data provide strong justification for the pursuit of CAR-
based therapy for other types of cancer, such as GBM.
To maximize the safety of the CAR approach, it is crit-
ical to select target antigens that allow specific targeting of
tumor cells [15]. Epidermal growth factor receptor variant
III (EGFRvIII) results from the in-frame deletion of exons
2–7 and the generation of a novel glycine residue at the
junction of exons 1 and 8 within the extra-cellular domain
of the EGFR, thereby creating a tumor-specific and im-
munogenic epitope reviewed in [16,17]. EGFRvIII ex-
pression has been seen in many tumor types, including
GBM, but is rarely observed in normal tissue. EGFRvIII is
expressed in 24% to 67% of GBM cases, and in patients
surviving ≥1 year, the expression of EGFRvIII is an inde-
pendent negative prognostic indicator [18,19].
With regard to the suitable effector T-cell phenotype
for anti-CNS tumor immunotherapy, our previous studieshave demonstrated that expression of IFN-γ by T-cells [20]
and the resulting expression of IFN-inducible protein (IP)-
10, also known as CXCL10, in the CNS tumor environment
[21,22], are critically important. These studies led us to in-
vestigate novel microRNA (miR)-mediated mechanisms in
the tumor-microenvironment [23] and in T-cell-based im-
munotherapy for GBM, as miRs can mediate a variety of
biological responses, including immune responses [24]. We
have demonstrated that miR-17-92, which is known to pro-
mote cell survival and proliferation [25], is the most sig-
nificantly up-regulated microRNA in IFN-γ-producing T
helper type-1 (Th1) cells but is down-regulated in patients
with GBM [26]. Our data also demonstrated that transduc-
tion of human T-cells to express miR-17-92 at high levels
promotes their survival and production of IFN-γ [26].
Based on these data, we evaluated our hypothesis that
transgene-derived overexpression of miR-17-92 improves
the therapeutic efficacy of CAR-transduced T-cells in a
preclinical model of GBM.
Results
Construction of lentiviral vectors for EGFRvIII-specific CAR
and miR-17-92
We generated a lentiviral vector for a CAR that recognizes
the EGFRvIII through a single-chain variable fragment
(scFv) derived from human EGFRvIII-specific monoclonal
antibody (mAb) 3C10 (pELNS-3C10-CAR; Figure 1A). In
this construct, the EF1α promoter drives the CAR fusion
protein integrating the 3C10-derived scFV, CD28 trans-
membrane (TM), and intracellular domains (ICD) as well
as the 4-1BB ICD and CD3ζ domains. We also created
a lentiviral miR-17-92 construct using the FG12-based self-
inactivating (SIN) vector (FG12-EF1a-miR-17/92; Figure 1B).
In this vector, the EF1α promoter drives miR-17-92, and the
human UbiC promoter drives enhanced green fluorescence
protein (EGFP) marker gene to track transduced cells.
In vitro characterization of human T-cells transduced with
the CAR and miR-17-92
We transduced healthy donor-derived CD3+ T-cells with
pELNS-3C10-CAR and evaluated expression levels of
the transgene (Figure 2A, Left). Using anti-mouse F(ab’)2
Ab, which is specific for the 3C10-derived scFv on human
T-cells, we detected nearly half (48.9%) of the T-cells ex-
pressing the 3C10-derived scFv on their surface.
To obtain human T-cells expressing both the CAR and
transgene-derived miR-17-92, we co-transduced CD3+ T-
cells with pELNS-3C10-CAR and FG12-EF1a-miR-17/92
by sequential infection of the two lentiviral vectors. At
24 hours after the initial transduction with pELNS-3C10-
CAR, we transduced the T-cells with FG12-EF1a-miR-17-
92. We observed that approximately one quarter (23.6%)
of the total T-cells expressed both CAR and EGFP (hence
the transgene-derived miR-17-92; Figure 2A, Right). For
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Figure 1 Schematic diagrams of lentiviral vectors for 3C10-CAR and miR-17-92. (A) The 3C10-CAR-expressing vector pELNS-3C10-CAR. The
EF1α promoter drives the CAR construct containing the 3C10 scFv for targeting of EGFRvIII. The CAR also incorporates CD28 as well as 4-1BB
and CD3ζ domains. (B) The miR-17-92-expressing lentiviral vector FG12-EF1a-miR-17/92. miR-17-92 is expressed under the control of the EF1a
promoter. The vector also contains the human UbiC promoter driving the EGFP as a marker gene for transduced cells. Abbreviations: RSV/HIV-1
5’LTR = Hybrid RSV promoter-R/U5 long terminal repeat; EF1α = Human elongation factor 1α-subunit promoter; VH = Variable region in the heavy
chain of the 3C10 immunoglobulin; VL = Variable region in the light chain of the 3C10 immunoglobulin; HIV-1 Δ-3′LTR = Self-inactivating 3′ long
terminal repeat with deletion in U3 region; CMV/HIV-1 5′LTR = Hybrid CMV promoter-R/U5 long terminal repeat; UbiC = Ubiquitin C promoter.
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T-cells (CAR-T-cells) by biotinylated anti-mouse F(ab’)2
Ab and anti-biotin MACS. By real-time PCR, we also de-
tected 3–4 fold higher expression of miR-17-92 in the
miR-17-92-co-transduced CAR-T-cells compared with T-
cells transduced with the CAR alone (Figure 2B).
While the mock-transduced T-cells showed only back-
ground levels of lysis against both parental U87 (EGFR-
vIII-negative) and U87-EGFRvIII cells, T-cells transduced
with the CAR demonstrated potent and specific lysis
of EGFRvIII-expressing U87 human GBM cells (U87-
EGFRvIII), with only background levels of cytotoxic effects
against parental U87 cells (Figure 2C). Co-transduction of
CAR-T-cells with miR-17-92 did not significantly enhance
their specific cytotoxic activity against U87-EGFRvIII tar-
get cells.miR-17-92 co-transduction enhances IFN-γ release and
reduces inhibition of proliferation of CAR-T-cells in the
presence of TMZ
In our previous study [26], CD4+ T-cells derived from
miR-17-92 transgenic mice demonstrated increased IFN-
γ production when compared with counterparts derived
from wild type mice, and transfection of human Jurkat
T-cells with miR-17-92 led to enhanced resistance to
activation-induced cell death. To extend these observa-
tions in a more clinically relevant setting, we evaluated
whether co-transduction of primary human CAR-T-cells
with miR-17-92 confers improved IFN-γ production and
cell proliferation. In addition, we determined the effects
on apoptosis after exposure to TMZ, a chemotherapyagent that is part of the standard-of-care in the treat-
ment of GBM [27].
Upon EGFRvIII-specific stimulation without TMZ, the
co-transduced CAR-T-cells expressed higher levels of
IFN-γ compared with CAR-T-cells without miR-17-92 co-
transduction (Figure 3A). When the cells were exposed to
escalating doses of TMZ, both cell types demonstrated
decreased IFN-γ production levels. However, the co-
transduced CAR-T-cells consistently demonstrated higher
IFN-γ production levels compared with CAR-T-cells with-
out miR-17-92 co-transduction at each of the evaluated
dose levels.
We next evaluated the effects of miR-17-92 co-
transduction on the proliferation of CAR-T-cells in the
presence of TMZ in culture (Figure 3B). To specifically
evaluate the impact of TMZ on the CAR-T-cell prolifer-
ation, we depicted the proliferation rate of the cells in
each group relative to the proliferation of the same cells
without TMZ. With increasing concentrations of TMZ,
proliferation of miR-17-92 co-transduced CAR-T-cells
was significantly less inhibited compared with the con-
trol CAR-T-cells. Without TMZ, miR-17-92-co-trans-
duced CAR-T-cells demonstrated a trend toward a more
rapid rate of proliferation compared with control CAR-
T-cells, but the difference was not significant (data not
shown).
We also evaluated whether miR-17-92-co-transduc-
tion would render CAR-T-cells more resistant to TMZ-
induced apoptosis. To this end, we conducted flow-
cytometric assessments of Annexin V+ and propidium
iodide (PI) staining of CAR-T-cells in the presence of
increasing concentrations of TMZ (Figure 3C and D).
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Figure 2 Functional expression of lentivirally transduced 3C10-CAR and miR-17-92 in human T cells. CD3+ T cells were transduced with
pELNS-3C10-CAR alone or with both pELNS-3C10-CAR and FG12-EF1a-miR-17/92 as described in Methods. (A) Transduced T-cells were evaluated
by flow cytometry for expression of 3C10-CAR and miR-17-92 by anti-mouse (Fab’)2 antibody and EGFP, respectively. (B) Expression levels of the
miR-17-92 cluster members miR-17-3p, miR-17-5p, and miR-92a-1 in transduced T cells were measured by qRT-PCR. Mean ± SD values of 3 replicate
measurements from one of three experiments with similar results are depicted. * indicates p < 0.05 between the two groups using student t-test.
(C) EGFRvIII-specific cytotoxic activities of transduced T cells evaluated by a 12-h 51Cr-release assay at various E:T ratios against 51Cr-labeled U87-EGFRvIII
or control U87 cells. Control cells were Mock (EGFP)-transduced T-cells. Values indicate mean ± SD in triplicated wells.
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Figure 3 Co-expression of miR17-92 in CAR-T-cells confers resistance to suppressive effects of TMZ. CAR-T-cells and those co-transduced
with miR-17-92 were co-cultured with aAPCs expressing EGFRvIII in the presence of the indicated concentrations of TMZ. (A-C) Open bars and
closed bars represent results from CAR-T-cells (without miR-17-72) and miR-17-92 co-transduced CAR-T-cells, respectively. (A) IFN-γ produced by
the transduced T cells during the last 24 h of 96 h co-culture. * indicates P < 0.05 for comparison of the two cell types at the given condition.
TMZ significantly suppressed IFN-γ production in each of the two cell types (P < 0.05 by one-way ANOVA). (B) Relative proliferation levels between
the groups were evaluated by WST1 assay following the 3-day co-culture. (C and D) Apoptotic death of CAR-T-cells evaluated by Annexin-V and
PI. (C) Mean fluorescent intensity for Annexin-V on CAR-T-cells exposed to TMZ. Values indicate mean ± SD in triplicate wells. (* indicates P < 0.05)
(D) Flow-cytometric histograms for Annexin-V+ and/or PI+ in one of the three experiments (all had similar results).
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(Annexin V+PI-) and late (Annexin V+PI+) apoptotic cells;
miR-17-92-co-transduced CAR-T-cells demonstrated a
lesser degree of apoptotic changes compared with con-
trol CAR-T-cells.Intravenous injection of CAR-T-cells in combination with
TMZ leads to complete remission of established U87-
EGFRvIII tumors in NSG mice
We next evaluated the efficacy of CAR-T-cells in immu-
nocompromised NOD/scid/γc(−/−) (NSG) mice bearing
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http://www.immunotherapyofcancer.org/content/1/1/21established (day 7) intracranial U87-EGFRvIII tumors. Mice
received a single intravenous (i.v.) infusion of miR-17-
92 co-transduced CAR-T-cells, CAR-T-cells without co-
transduction of miR-17-92, or mock-transduced T-cells
(2 × 106/mouse) via the tail vein. As newly diagnosed GBM
patients routinely receive TMZ therapy, we also admi-
nistered intraperitoneal (i.p.) daily injections of TMZ for
5 days starting on the day of T-cell infusion (Figure 4A and
Additional file 1: Figure S1).
TMZ treatment itself was ineffective: all the control
mice receiving TMZ and mock-transduced T-cells died
within 3 weeks after the T-cell infusion (Figure 4B). Al-
though 1 of 10 mice with CAR-T-cells and 2 of 10 mice
with miR-17-92 co-transduced CAR-T-cells died by day
22 as a result of tumor progression, all the other mice in
these groups survived longer than 40 days. Indeed, bio-
luminescence imaging (BLI) signal levels in these surviving
mice diminished to background levels by day 35, consist-
ent with tumor eradication in these mice (Figure 4C).
There was not a statistically significant difference in
survival of the mice receiving miR-17-92-co-transducedA
B C
0 10 20 30 40
0
20
40
60
80
100
Mock
3C10
3C10+miR
Days after T-cell Infusion
P
er
ce
n
t 
su
rv
iv
al
p=0.5567
Day-7 
I.C. inoculation of 
U87-EGFRvIII
5x10e4/mouse
I.P. injec
Figure 4 Robust therapeutic effects of CAR-T-cells in mice bearing U8
mice received i.c. inoculation of 5×104 U87-EGFRvIII-Luc cells on day −7 and s
pELNS-3C10-CAR alone or with both pELNS-3C10-CAR and FG12-EF1a-miR-17
(0.33 mg/mouse/day) on days 0–4. (B) Kaplan-Meier analysis. Median survival
miR-17-92; n = 10/group) was significantly greater compared with the mice tr
(n = 5) died by day 21. (C) Longitudinal measurements of tumor-derived mea
was defined based on the levels observed in non-tumor-bearing mice imaged
independent experiments with similar results.CAR-T-cells versus CAR-T-cells without miR-17-92 co-
transduction (log-rank test: p = 0.5567).
We also evaluated the effect of 3C10-CAR-T-cells with-
out TMZ treatment (Additional file 1: Figure S2). While
direct intra-tumoral injection of 3C10-CAR-T-cells eradi-
cated the U87-EGFRvIII tumors without TMZ treatment
(data not shown), i.v. infusion of 3C10-CAR-T-cells without
TMZ was ineffective, regardless of whether the T-cells were
co-transduced with miR-17-92, suggesting U87-EGFRvIII
tumors were extremely aggressive without TMZ-treatment
(Additional file 1: Figure S2).
miR-17-92 co-transduced CAR-T-cells confers long-term
protection against U87-EGFRvIII tumors in mice
To determine whether CAR-T-cells can provide long-term
protection against U87-EGFRvIII tumors, we re-challenged
the survivors in the experiment described above (Figure 4)
with inoculation of U87-EGFRvIII cells in the contra-
lateral hemisphere of the brain on day 49 post T-cell in-
fusion (Figure 5). Prior to this experiment, our preliminary
data demonstrated that i.v. infused 3C10-CAR-T-cells0 7 14 21 31 35
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Figure 5 Ectopic expression miR-17-92 in CAR-T cells confers improved protection following tumor re-challenge. (A) Schematic of the
experimental protocol. CAR-T-cell-treated mice that survived at least for 35 days in the experiment shown in Figure 4 [4 mice receiving 3C10-T-
cells without miR and 3 mice treated with T-cells co-transduced with 3C10 plus miR-17-92] received i.c. re-challenge with U87-EGFRvIII-Luc cells
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tissue (Additional file 1: Figure S3) and persisted, with
transgene-derived expression of the CAR in the spleen for
more than 60 days (Additional file 1: Figure S4). While the
re-challenged tumor cells grew in all four mice treated with
CAR-T-cells, none of three mice treated with miR-17-92-
co-transduced CAR-T-cells demonstrated BLI signal be-
yond background levels. These results strongly suggest that
co-transduction of miR-17-92 cluster promotes the long-
term persistence and function of CAR-T-cells, thereby pro-
viding prolonged protection against tumor growth.
Discussion
To our knowledge, this is the first gene transfer study
evaluating the potential of miR-17-92 to enhance cancer
immunotherapy. Our data show that co-expression of
miR-17-92 confers improved resistance to the effects of
TMZ on T-cells. In vivo, T-cells co-transduced with both
3C10-CAR and miR-17-92 demonstrated more persist-
ent therapeutic effects compared with T-cells transduced
with 3C10-CAR alone.
Lentiviral transduction of miR-17-92 in our study con-
fers ectopic over-expression of the miR-cluster in trans-
duced T-cells. During the physiological T-cell activation
and differentiation processes, however, expression levels
of endogenous miR-17-92 in T-cells appear to be tightlyregulated. In human CD8+ T cells, miR-17-92 expression
is high in naïve cells but diminishes as the cells differenti-
ate [28]. In a mouse model of lymphocytic choriomeningi-
tis virus infection, miR-17-92 is strongly up-regulated
following T-cell activation but is later down-regulated fol-
lowing clonal expansion and is further silenced during
memory development [29]; in this study, miR-17-92 was
necessary for rapid T-cell expansion and IFN-γ expression,
and failure to down-regulate miR-17-92 led to a gradual
loss of memory cells and defective central memory cell de-
velopment [29]. These observations are not necessarily
consistent with our results, as we observed the persistence
of miR-17-92-co-transduced CAR-T-cells and protec-
tion of the mouse brain against tumorigenesis when re-
challenged with U87-EGFRvIII cells. It is possible that our
observation is attributable to the combined effects of miR-
17-92 and the co-stimulatory molecules provided by the
CAR.
We did not evaluate the specific function of each miR in
the miR-17-92 cluster. However, it has been recently shown
that miR-17 and miR-19b are critical for Th1 responses,
with miR-17 and miR-19b targeting TGFβRII and Pten
(phosphatase and tensin homolog), respectively [30,31].
These two miRs mediate T-cell proliferation, protection
from activation-induced cell death, IFN-γ production, and
inhibition of regulatory T-cell development [30,31]. Hence,
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TGFβRII in miR-17-92-transduced T-cells (data not shown),
we must consider whether miR-17 and miR-19b alone are
sufficient to mediate the observed enhancement of anti-
GBM efficacy in our CAR therapy. Furthermore, gluco-
corticoids, which are often used in the management of
GBM, repress the expression of miR-17-92 in lympho-
cytes, thereby up-regulating proapoptotic Bim as a mech-
anism inducing apoptotic death of lymphoid cells [32].
Together with the results from our current study, these
data provide further rationale for the incorporation of
miR-17-92 CAR designs.
Although miR-17-92 has been described as an onco-
genic miR [33], miR-17-92 overexpression itself is known
not to be oncogenic in lymphocytes [25]. Indeed, we did
not observe any uncontrolled proliferation of miR-17-92-
transduced T-cells in the current study. Nonetheless, as
an alternative approach for improved safety, transient
transduction of T-cells with miR-17-92 itself, instead of
lentiviral stable transfer, and multiple injections of these
T-cells, may represent a reasonable approach without the
associated safety concerns of integrating viral vectors [34].
With regard to the inclusion of co-stimulatory signals
in CAR constructs, the current study focused on the use
of a “third generation” system. It would be interesting to
directly compare second generation (i.e., the CAR con-
struct with 4-1BB plus CD3zeta chain without CD28)
versus third generation CARs in our tumor model, and
we have in fact undertaken such a comparative study
(manuscript in preparation).
In support of EGFRvIII-targeted CARs for therapy of
GBM, Morgan et al. recently evaluated scFv sequences de-
rived from seven different anti-EGFRvIII mAbs, including
3C10 and humanized 139, in γ-retroviral CARs [35]. Based
on their in vitro characterization, the 3C10 and the 139
CARs were two of the three clones that yielded specific
IFN-γ production in response to EGFRvIII-expressing tar-
get cells but not to cells expressing wild-type EGFR. How-
ever, they did not evaluate the efficacy of EGFRvIII CAR-T
cells in animal models.
Of course, EGFRvIII is expressed only in a subpopulation
of GBM patients and in only a fraction of GBM cells, even
in “EGFRvIII-positive” cases [19]. Although a recent report
on a phase II vaccine study targeting the EGFRvIII epitope
in newly diagnosed GBM patients demonstrated encour-
aging results as reflected in overall survival [36], immuno-
therapy targeting EGFRvIII as a single target will likely
result in growth of GBM cells that have down-regulated the
immunotherapy-targeted antigen [36]. Hence, we are cur-
rently working to develop CARs that target other GBM-
relevant antigens. Several previous studies have developed
CARs against GBM-associated antigens, such as IL-13Rα2
[37,38], HER-2 [39], and EphA2 [40]. We anticipate that an
effective CAR therapy would use T-cells capable of resistingGBM-induced suppression mechanisms and targeting mul-
tiple antigens, such that the infused T-cells would exhibit
effective and sustained therapeutic effect against tumors
with heterogeneous antigen-expression profiles.
Although EGFRvIII is an attractive target for GBM ther-
apy, a GBM-derived cell line that preserves EGFRvIII ex-
pression without transgene-derived EGFRvIII had not
existed until Schulte et al. recently established such a cell
line without EGF supplementation in the culture [41].
Additional studies are warranted to evaluate the potency
of CARs that target EGFRvIII using GBM cells that ex-
press endogenous EGFRvIII, such as that conducted by
Morgan et al. [35].
To evaluate the effects of EGFRvIII stimulation on
CAR-T-cells, we used an artificial antigen-presenting
cell (aAPC) line K562-CD32-CD80-41BBL [42] that had
been transduced with EGFRvIII. aAPC offers a reprodu-
cible, cost-effective, and convenient method for polyclonal
and antigen-specific expansion of human T cells for adop-
tive immunotherapy. Although the possibility exists that
aAPCs could introduce confounding signals, we were able
to obtain similar results when we used CD28/CD3 beads
for T-cell stimulation (data not shown), suggesting no
such signals from the aAPCs disturbed our data.
Our in vivo data demonstrate that the therapeutic effi-
cacy of CAR-T-cells can be achieved only with pretreat-
ment with TMZ. We speculate that the major effect of
TMZ therapy is a reduction in tumor burden, but TMZ
could enhance the efficacy of CAR-T-cell therapy through
other mechanisms. As contrasting results have been re-
ported with regard to the role of TMZ in glioma immuno-
therapy [43,44], we are currently evaluating the effects of
TMZ specifically on the glioma microenvironment using
syngeneic glioma models. Human GBM patients receive
oral administration of 150–200 mg/m2/day as standard-of
care [27], in which case peak serum TMZ concentrations
of up to 100 μM [45]. We used these clinically relevant
concentrations of TMZ in designing our in vitro studies to
evaluate the effects of TMZ.
Other experimental parameters must be taken into ac-
count to optimize i.v. infused T-cell therapy in gliomas,
such as factors that promote the homing of T-cells to the
tumor (e.g., T-cell expression of very late activation anti-
gen (VLA)-4 [46,47] and chemokine receptor CXCR3
[21,22]). While these factors cannot be precisely evaluated
in our NSG mouse model, we will consider these markers
in optimizing clinical trials for glioma CAR therapy.
Conclusions
Our 3rd generation CAR targeting EGFRvIII demon-
strated an antigen-specific and potent efficacy in mice
bearing EGFRvIII-expressing GBM xenografts. Further-
more, co-expression of miR-17-92 in CAR-T-cells en-
hanced durability of the therapeutic response. Our study
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grates miR-17-92, with a focus on the safe and effective
delivery of the miR-17-92 cluster in CAR-transduced T-
cells.
Methods
Cell lines
The GBM cell line U87-EGFRvIII was kindly provided by
Dr. Shiyuan Chang (Northwestern University, Chicago, IL).
The aAPC line K562-CD32-CD80-41BBL [42] and
U87MG cell lines were maintained in RPMI-1640 medium
containing 10% fetal bovine serum (FBS) and penicillin/
streptomycin. Geneticin was added to maintain the U87-
EGFRvIII cell line. The U87-EGFRvIII-Luc cell line was
generated by transduction of U87-EGFRvIII cells with a re-
combinant lentivirus encoding luciferase of Photinuspyralis
(provided by Dr. Stephen H. Thorne at University of
Pittsburgh, Pittsburgh, PA) and subsequent selection by
blasticidin for a clone expressing the highest level of
luciferase.
Construction of SIN lentiviral vectors
The mAb 3C10 was originally developed by the im-
munization of mice with a 14-amino acid peptide that
incorporates the EGFRvIII-specific fusion junction [48].
Subsequently, its scFv was cloned [49]. The scFv portion in
the pELNS-SS1CD28r1BBZeta [12] was replaced with the
cDNA for the 3C10 scFV by gene synthesis (Genscript,
Piscataway, NJ) to create pELNS-3C10-CAR. FG12-EF1α-
miR-17/92 was generated based on FG12 (obtained from
Chang-Zhen Chen at Stanford University through Addgene,
plasmid #11375). PCR-amplified EF1α promoter fragment
(with XbaI site on 5′ end and XhoI site on 3′ end) and the
miR-17-92 pre-miRNA (synthesized by GenScript Corpor-
ation, Piscataway, NJ; with XhoI site on 5′ end and PacI site
on 3′ end) were subcloned into the FG12 cassette using its
XbaI and PacI sites.
Preparation of lentiviral vectors
HEK293T cells (8 × 106) were plated on 175 cm2 flask.
At 24 h, SIN vector, pMDLg/pRRE, pRSV-Rev, and
pMD2.G were co-transfected by X-tremeGENE 9 (Roche
Applied Science Roche, Penzberg, Germany). Super-
natant was collected at 48 h, mixed with PEG-it™ Virus
Precipitation Solution (5×) (SBI, San Jose, CA), and in-
cubated for 24 h at 4°C. The supernatant/PEG-it mixture
was then centrifuged at 1500 × g for 30 minutes at 4°C,
and the pellet was re-suspended in 1/10 of the original
volume using cold, sterile medium containing 25 mM
HEPES buffer at 4°C and stored at −80°C.
T-cell isolation
Human T-cells were isolated from healthy donor-derived
peripheral blood mononuclear cells by negative selectionusing the Pan T-Cell Isolation Kit II (Miltenyi BiotecInc.,
Auburn, CA).
Transduction of T-cells by lentiviral vectors
The isolated T-cells (4×106) were re-suspended in 4 ml
medium per well of a 6-well plate and stimulated with
Dynabeads Human T-Activator CD3/CD28 and IL-2
(Peprotech, 100 unit/ml) for 24 h. Next, the media (3 ml/
well) was gently removed without disturbing clustering T
cells, and the lentiviral pELNS-3C10-CAR vector super-
natant (x10; 3 ml/well) was added (the final MOI ~ 5–6).
T-cells were then cultured with the lentiviral vector for
24 h in RPMI1640 containing 10% FBS and IL-2 (100 unit/
ml). For co-transduction, after the first transduction with
the lentiviral CAR vector, the T-cells were subsequently in-
fected with FG12-EF1α-miR-17/92 in RPMI1640 contain-
ing 10% FBS and IL-2 (100 unit/ml) for additional 24 h.
Purification of 3C10-CAR-T-cells
CAR-T-cells were detected by biotin-SP-AffiniPure F(ab')2
fragment-specific goat anti-mouse IgG (Jackson Immuno
Research Laboratories, West Grove, PA) and streptavidin-
Phycoerythrin (PE) (BD Pharmingen, San Diego, CA).
CAR-T-cells were enriched using the biotin-SP-AffiniPureF
(ab')2 fragment-specific goat anti-mouse IgG and Streptavi-
din Micro Beads (Miltenyi Biotec Inc.) according to the
manufacturer’s instructions. The purity of the isolated
CAR-T-cells was > 90% (Additional file 1: Figure S5).
Cell proliferation and cytokine release assays
aAPCs expressing EGFRvIII were generated by trans-
fection of EGFRvIII-expression vector (PT3.5/CMV-
EGFRvIII) using Amaxa Nucleofector System (Lonza,
Walkersville, MD). Aliquots of 2 × 104 T-cells were co-
cultured with 2 × 104 γ-irradiated aAPC in each well of
96-well plates and treated with graded concentrations of
TMZ (Sigma-Aldrich, St. Louis, MO) for 72 h. Spectro-
photometric quantification of T-cell proliferation was per-
formed by using the metabolic proliferation reagent WST-
1 (Roche Applied Science) according to the manufacturer’s
instructions. The absorbance of the samples against a
background control as blank (media) was measured at
450 nm by using a Multiscan Ascent microplate (ELISA)
reader (Thermo Scientific, Rockford, IL). For evaluation of
IFN-γ-release, following the 72 h co-culture, T-cell were
cultured with new aAPC for an additional 24 h, and cul-
ture supernatants were assessed for IFN-γ using a specific
ELISA kit (GE Healthcare Bio-Sciences).
Target cell lysis
The susceptibility of U87MG and U87-EGFRvIII cells to
cytolysis by the CAR-T-cells was evaluated using a stand-
ard 12-h 51Cr-release assay at various effector:target (E:T)
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follows:
100 × (experimental release − spontaneous release)/
(maximum release − spontaneous release)
Detection of apoptotic cells
Apoptotic cells were quantified by staining for Annexin
V and propidium iodide (PI) using the Annexin V-APC
apoptosis detection kit, according to the manufacturer’s
instructions (BD Biosciences, San Jose, CA). The cells
were analyzed with Accuri C6 (BD Accuri Cytometers,
Ann Arbor, MI) or FACS Caliber (Becton Dickinson,
Pont de Claix, France) flow cytometer.
Therapy of mice bearing intracranial glioma xenografts
5- to 6-week-old NOD/Shi-scid,IL-2Rr KO Jic (NOG) fe-
male mice (Jackson Laboratory, Bar Harbor, ME) were
used in the experiments. Animals were handled in the
Animal Facility at the University of Pittsburgh per an In-
stitutional Animal Care and Use Committee-approved
protocol. The procedure has been described previously by
us21. Briefly, using a stereotactic apparatus, mice received
5×104 U87EGFRvIII cells/mouse in 2 μl PBS at 2 mm lat-
eral to the bregma and 4 mm below the surface of the
skull. Seven days after tumor inoculation, each mouse re-
ceived i.v. infusion of 2 × 106 CAR-T-cells, with or without
co-transduction of miR-17-92, or mock-transduced T-
cells via the tail vein. On days 0–4 after T-cell infusion,
mice received i.p. administration of TMZ (333 μg/dose).
Symptom-free survival following the tumor inoculation
was monitored. The growth of U87EGFRvIII-Luc tumors
in the brain was non-invasively monitored by BLI using
the in vivo imaging system IVIS (PerkinElmer, Alameda,
CA). Mice received i.p. injection of with 200 μl (15 mg/
ml) of freshly thawed aqueous solution of D-Luciferin po-
tassium salt (PerkinElmer), were anesthetized with isoflur-
ane, and imaged for bioluminescence for 1 sec exposure
time. Optical images were analyzed by IVIS living image
software package. The mice that rejected the estab-
lished U87-EGFRvIII tumors received intracranial (i.c.) re-
challenge with 5×105 U87-EGFRvIII cells at the same
stereotactic coordinates on day 49.
Real time-PCR
Total RNA was extracted using the Qiagen RNeasy kit
(Qiagen, Hilden, Germany), and purity was confirmed
with an A260/A280 ratio greater than 1.85. RNA was
subjected to RT-PCR analysis using the TaqMan micro-
RNA Reverse Transcription Kit, microRNA Assays (Ap-
plied Biosystems), and the Step One Real-Time PCR
System (Applied Biosystems, Foster City, CA). The small
nucleolar RNU43 was used as the housekeeping small
RNA reference gene for human samples. All reactionswere done in triplicate, and relative expression of RNAs
was calculated using the ΔΔCT method.
Statistical analyses
All statistical analyses were carried out on Graphpad Prism
software. For in vitro studies, Student-t or one-way
ANOVA test was used to compare two groups or more
than two groups, respectively. For in vivo studies, log-rank
test or Wilcoxon rank-sum test was used to compare
symptom-free survival or tumor size, respectively. We con-
sidered differences significant when p < 0.05.
Additional file
Additional file 1: Figure S1. Efficacy of CAR-T-cells in mice. Mice received
i.c. inoculation of 5×104 U87-EGFRvIII cells on day −7, and subsequently
received i.v. infusion of 2×106 CAR-T-cells with/without miR or mock-
transduced T-cells on day 0. All mice received i.p. administration of TMZ (0.33
mg/mouse/day) on days 0–4. Colored images represent photon flux signals
from U87EGFRvIII-Luc tumors. Figure S2. CAR-T-cells did not exert
therapeutic effects without TMZ. Mice received i.c. inoculation of 1×105
U87-EGFRvIII-Luc cells on day −7, and subsequently received 2×106 T-cells on
day 0. (A) Longitudinal measurements of tumor-derived mean photon flux ±
SD. (B) Kaplan-Meier plots for survival of the mice treated with mock-
transduced T-cells or CAR-T cells (with or without co-transduction of miR-17-
92) (n = 5/group). Figure S3. Efficient homing and persistence of CAR-T-cells
in U87-EGFRvIII tumors. Mice treated with TMZ and CAR-T-cells were
sacrificed on day 14 following the tumor re-challenge per data in Figure 5.
(A and B) A low (A; x4) or high (B; x20) magnification view of a section stained
with hematoxylin and eosin. (C and D) CAR-T-cell infiltration in the i.c. tumor
detected by immuno-fluorescence imaging with (D) or without (C) biotin-
conjugated anti-F(ab’)2 mAb and streptavidin-PE. The counter staining with
DAPI (blue) indicates cells in the tissue. Figure S4. The number of spleen cells
in mice after CAR-T-cells treatment. Treated mice were sacrificed on Day 21
following the tumor re-challenge per data in Figure 5. The number of
splenocytes were calculated and stained with anti-human CD8, CD4 and anti-
mouse F(ab’)2 antibody for detection of CAR-expressing T-cells. N = 3/group.
Figure S5. CAR-T-cell selection with magnetic beads for in vitro study. Three
days after transduction of CAR, T-cells were selected using biotin-anti-mouse
F(ab’)2 antibody in conjunction with streptavidin-ferromagnetic beads. The
selected cells were stained with biotin-anti-mouse F(ab’)2 antibody and
streptavidin-PE.
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